斑块状银屑病-话题@MedSci

#斑块状银屑病#

28篇内容 | 1821人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1449594, encodeId=e4bd14495945c, content=<a href='/topic/show?id=446f5e934a9' target=_blank style='color:#2F92EE;'>#斑块状银屑病#</a>, objectTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, objectType=article, longId=175399, objectId=02b91e539906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02b91e539906, replyNumber=0, likeNumber=85, createdTime=2019-07-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02b91e539906, moduleTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02b91e539906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449593, encodeId=149a14495931b, content=<a href='/topic/show?id=446f5e934a9' target=_blank style='color:#2F92EE;'>#斑块状银屑病#</a>, objectTitle=诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状, objectType=article, longId=173291, objectId=9eb91e32918d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9eb91e32918d, replyNumber=0, likeNumber=78, createdTime=2019-06-28, rootId=0, userName=gous, userId=1ecb5492626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9eb91e32918d, moduleTitle=诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9eb91e32918d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449592, encodeId=2fb814495929d, content=<a href='/topic/show?id=446f5e934a9' target=_blank style='color:#2F92EE;'>#斑块状银屑病#</a>, objectTitle=Arthritis Rheumatol：中重度慢性斑块状银屑病患者乌司奴单抗治疗后，外周亚临床肌腱端病的消退, objectType=article, longId=154386, objectId=194315438605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=194315438605, replyNumber=0, likeNumber=90, createdTime=2018-11-27, rootId=0, userName=gous, userId=1ecb5492626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=194315438605, moduleTitle=Arthritis Rheumatol：中重度慢性斑块状银屑病患者乌司奴单抗治疗后，外周亚临床肌腱端病的消退, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=194315438605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449591, encodeId=dac5144959167, content=<a href='/topic/show?id=446f5e934a9' target=_blank style='color:#2F92EE;'>#斑块状银屑病#</a>, objectTitle=澳大利亚TGA批准ILUMYA（tildrakizumab）用于治疗中重度斑块状银屑病, objectType=article, longId=149465, objectId=46e31494650f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46e31494650f, replyNumber=0, likeNumber=89, createdTime=2018-09-25, rootId=0, userName=gous, userId=1ecb5492626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46e31494650f, moduleTitle=澳大利亚TGA批准ILUMYA（tildrakizumab）用于治疗中重度斑块状银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46e31494650f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449590, encodeId=94a81449590af, content=<a href='/topic/show?id=446f5e934a9' target=_blank style='color:#2F92EE;'>#斑块状银屑病#</a>, objectTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, objectType=article, longId=149073, objectId=52291490e33c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52291490e33c, replyNumber=0, likeNumber=68, createdTime=2018-09-20, rootId=0, userName=gous, userId=1ecb5492626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52291490e33c, moduleTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52291490e33c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449589, encodeId=1548144958942, content=<a href='/topic/show?id=446f5e934a9' target=_blank style='color:#2F92EE;'>#斑块状银屑病#</a>, objectTitle=Lancet：risankizumab对中重度斑块状银屑病的疗效和安全性, objectType=article, longId=146414, objectId=e01b14641415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01b14641415, replyNumber=0, likeNumber=0, createdTime=2018-08-13, rootId=0, userName=gous, userId=1ecb5492626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01b14641415, moduleTitle=Lancet：risankizumab对中重度斑块状银屑病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e01b14641415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449588, encodeId=4d381449588d6, content=<a href='/topic/show?id=446f5e934a9' target=_blank style='color:#2F92EE;'>#斑块状银屑病#</a>, objectTitle=ICER：Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处, objectType=article, longId=145944, objectId=6e0014594413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e0014594413, replyNumber=0, likeNumber=96, createdTime=2018-08-07, rootId=0, userName=gous, userId=1ecb5492626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e0014594413, moduleTitle=ICER：Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e0014594413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449587, encodeId=0356144958ecb, content=<a href='/topic/show?id=446f5e934a9' target=_blank style='color:#2F92EE;'>#斑块状银屑病#</a>, objectTitle=苏格兰药物联盟批准Kyntheum用于中重度斑块状银屑病患者, objectType=article, longId=138000, objectId=6853138000b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6853138000b3, replyNumber=0, likeNumber=68, createdTime=2018-05-14, rootId=0, userName=gous, userId=1ecb5492626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6853138000b3, moduleTitle=苏格兰药物联盟批准Kyntheum用于中重度斑块状银屑病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6853138000b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

斑块状银屑病

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#斑块状银屑病#

NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病

2019-07-15

gous (审核中...)

前往app查看评论内容

#斑块状银屑病#

诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状

2019-06-28

gous (审核中...)

前往app查看评论内容

#斑块状银屑病#

Arthritis Rheumatol：中重度慢性斑块状银屑病患者乌司奴单抗治疗后，外周亚临床肌腱端病的消退

2018-11-27

gous (审核中...)

前往app查看评论内容

#斑块状银屑病#

澳大利亚TGA批准ILUMYA（tildrakizumab）用于治疗中重度斑块状银屑病

2018-09-25

gous (审核中...)

前往app查看评论内容

#斑块状银屑病#

III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性

2018-09-20

gous (审核中...)

前往app查看评论内容

#斑块状银屑病#

Lancet：risankizumab对中重度斑块状银屑病的疗效和安全性

2018-08-13

gous (审核中...)

前往app查看评论内容

#斑块状银屑病#

ICER：Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处

2018-08-07

gous (审核中...)

前往app查看评论内容

#斑块状银屑病#

苏格兰药物联盟批准Kyntheum用于中重度斑块状银屑病患者

2018-05-14

科室
- - 订阅+
  - 更多科室
工具
服务